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ABSTRACT:  This study’s objective was to esti-
mate net returns and return risk for antimicrobial 
metaphylaxis options to manage bovine respira-
tory disease (BRD) in high health-risk feedlot 
cattle. The effectiveness of antimicrobials for 
metaphylaxis varies by cattle population. How 
differing antimicrobial effectiveness translates to 
net return profitability for heterogeneous cattle 
populations is less understood. Net returns and 
return risk were assessed using a net return sim-
ulation model adapted to allow for heterogeneity 
in high health-risk cattle placement characteristics 
and antimicrobial choice to control BRD. The net 
return model incorporated how antimicrobials 
modify BRD health and performance outcomes. 
Health and performance outcomes were calibrated 
from published literature and proprietary feedlot 
data. Proprietary data came from 10 Midwestern 
feedlots representing nearly 6 million animals and 
50,000 cohorts. Twelve placement-by-metaphylaxis 
decision combinations were assessed: high health-
risk steer placement demographics were 600 or 800 
lb steers placed in Winter (Oct–Mar) or Summer 
(Apr–Sept) managed with one of three different 
health programs: “no metaphylaxis,” “Upper Tier” 
antimicrobial, or “Lower Tier” antimicrobial. Net 
return distributions were compared between “no 
metaphylaxis” and a specific antimicrobial tier 
within specific cattle populations. We found the 
expected incremental net return of administering 
an “Upper Tier” (“Lower Tier”) antimicrobial 
for metaphylaxis compared to “no metaphylaxis” 
for high health-risk steers was $122.55 per head 
($65.72) for 600 lb and $148.65 per head ($79.65) 
for 800 lb winter placements. The incremental 
expected net return and risk mitigated by meta-
phylaxis varied by placement weight, season, and 
antimicrobial choice. The probability net returns 
would decline by at least $50 per head was signif-
icantly reduced (from approximately 4% to 40%) 
when any antimicrobial was used on high health-
risk steers. Both tiers of antimicrobials used for 
metaphylaxis increased expected net returns and 
decreased net return variability relative to no met-
aphylaxis. Thus, feedlots were more certain and 
realize a greater profit on high health-risk pens of 
steers when metaphylaxis was used. This occurred 
because the reduction in cattle health and perfor-
mance outcomes using any antimicrobial was suffi-
ciently large to cover added initial and subsequent 
antimicrobial costs. Results aid in assessing meta-
phylaxis strategies in high health-risk cattle.
Key words: antimicrobial, bovine respiratory disease, cattle, economic simulation,  
metaphylaxis, net returns
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INTRODUCTION
Antimicrobials used to improve the well-being, 
health, and performance of cattle arriving at feed-
lots have received considerable public attention. 
Metaphylaxis, administration of an antimicrobial, 
generally via injection, is used by 39% of U.S. feed-
lots with 1000+ head capacity selectively on 17% 
of cattle to reduce adverse effects of bovine re-
spiratory disease (BRD) in high health-risk cattle 
(United States Department of Agriculture, 2019). 
Randomized control trials have generally confirmed 
metaphylaxis can reduce morbidity and mortality 
in feedlot cattle where health-risk susceptibility is 
high (O’Connor et  al., 2013; Abell et  al., 2017). 
Categorization as high health risk generally refers 
to cattle with one or more risk factors for BRD, 
which may include unknown health history, recent 
weaning, and various source and transport stress-
ors (Nickell and White, 2010; Ives and Richeson, 
2015; Smith et al., 2017).
When cohorts of cattle arrive at feedlots, feed-
lots assess animal health risks and decide whether 
to manage cattle with metaphylaxis. Perceived 
benefits of metaphylaxis for reducing cattle mor-
bidity and mortality are weighed against costs 
to process, treat, and monitor cattle during their 
time on feed. If  metaphylaxis is elected, feedlots 
must select the type of antimicrobial to admin-
ister (Nickell and White, 2010). The selection of 
the specific antimicrobial to use is primarily based 
on veterinary consultation, past experience, and 
duration of action (United States Department of 
Agriculture, 2013). While the effectiveness and cost 
of antimicrobials used for metaphylaxis vary, how 
these differences translate into expected net return 
distributions for heterogeneous cattle has not been 
described (DeDonder and Apley, 2015; Ives and 
Richeson, 2015).
Realized cattle morbidity and mortality condi-
tional on antimicrobial choice and administration 
are unknown until after cattle harvest. As such, 
animal health outcomes are uncertain when the 
metaphylaxis decision is made. Stochastic net re-
turn simulations have been used to value BRD for 
dairy, cow-calf, and feedlot cattle (Van der Fels-
Klerx et al., 2001; Buhman et al., 2003; Nor et al., 
2012; Theurer et al., 2015; Wang et al., 2018) and to 
value animal health protocols such as metaphylaxis 
in feedlot cattle (Dennis et  al., 2018). Stochastic 
simulations are distinctly different than determin-
istic simulations because they incorporate uncer-
tainty via probability distributions obtained from 
historical data, expert opinion, and/or published 
literature. However, no studies have examined how 
net returns differ by the type of antimicrobial used 
for metaphylaxis across different cattle placement 
demographics.
The objective of this study is to measure net 
return and return risk between “Upper Tier” and 
“Lower Tier” antimicrobials used for metaphylaxis 
and a “no metaphylaxis” option in high health-risk 
feedlot cattle. In particular, we test whether ex-
pected net return distributions vary across cattle 
placement weight, placement season, and anti-
microbial tier administered.
MATERIALS AND METHODS
Cattle feeding net returns vary across man-
agement, marketing, and animal health protocols. 
Cattle feeding net return distributions are esti-
mated using a variation of  the stochastic simula-
tion model developed by Dennis et al. (2018). The 
primary purpose of  Dennis et al. (2018) was to es-
timate the economic value of  metaphylaxis to the 
U.S.  fed cattle industry. This economic value was 
then used to determine how removing metaphy-
laxis as an animal health protocol would impact 
feedlots, processors, and consumers. In order to 
calculate the overall industry-level impact of  met-
aphylaxis, the authors used an “average” animal 
gender, placement season, and antimicrobial used. 
We modify their simulation method by allowing 
placement season, weight, and antimicrobial 
used for metaphylaxis to vary. In what follows, we 
briefly describe the cattle feeding economic deci-
sion framework used in our stochastic simulation 
emphasizing how we incorporate heterogeneity 
into the Dennis et al. (2018) cattle feeding net re-
turn simulation model.
Cattle Feeding Net Return Stochastic Simulation
We consider four types of high health-risk 
steers purchased by feedlots—two cattle place-
ment weights (600 or 800 lb) and two placement 
seasons (Oct–Mar referred to as “Winter” or Apr–
Sept referred to as “Summer”). In our simulation, 
we considered three different health management 
options for high health-risk steers: “no metaphy-
laxis,” “Upper Tier” antimicrobial, or “Lower Tier” 
antimicrobial. High health-risk cattle are cattle that 
are classified to be at-risk for BRD and should be 
managed with metaphylaxis. Antimicrobials were 
categorized into “Upper” and “Lower” tiers based 
on categorizations from the work of Abell et  al. 
(2017) where they classified antimicrobials into 
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tiers conditional on odds ratio (OR) confidence 
intervals for different morbidity and mortality 
outcomes. Thus, our simulation compared eight 
different metaphylaxis scenarios (one gender, two 
placement weights, two seasons, and two tiers of 
antimicrobials used for metaphylaxis) to four “no 
metaphylaxis” scenarios (one gender, two place-
ment weights, two seasons).
Regardless of  initial health status and health 
management strategy, cattle can become sick and/
or die. Feedlots realize final morbidity and mor-
tality only at cattle harvest. In our model, all cattle, 
regardless of  initial health-risk status, possessing 
clinical signs of  BRD are pulled and treated. Sick 
cattle incur greater health costs (HC ↑), gain less 
weight per day during feeding (ADG ↓), and re-
quire more feed to gain an additional pound of 
weight (AFC ↑) (Tennant et al., 2014). Feedlots do 
not sell dead animals (CSW  =  0) losing the ini-
tial cost of  the feeder (FDRC) plus any cost for 
yardage (YC ≥ 0), feed (FC ≥ 0), interest (IC ≥ 0), 
and health treatments (HC ≥ 0). Morbidity and 
mortality combine to increase total feeding costs 
(TC ↑) effectively decreasing profit (π ↓). Mortality 
poses a high cost to feedlots and is the primary 
driver of  net return and return risk in our sto-
chastic simulation.
After initial processing, cattle that survive and 
reach an expected harvest weight are sold on a 
live-weight basis. Thus, feedlots choose the type of 
cattle to purchase, initial and supplemental health 
protocols, and cattle target finish weight. Given 
this, cattle feeding net returns (π) per head for a 
given cohort of cattle can be specified as (Dennis 
et al., 2018):
pi = TR︸︷︷︸
Total revenue
− FDRC− YC− FC− HC− IC︸ ︷︷ ︸
Total costs
 (1)
TR︸︷︷︸
Total revenue
= FP︸︷︷︸
Fed Price
× { CSW︸ ︷︷ ︸
Finshed weight
× (1− SHRINK)︸ ︷︷ ︸
Transportation weight loss
× (1−MORT− ICLL) }︸ ︷︷ ︸
Lbs. of animals solds
)
︸ ︷︷ ︸
Total costs
+(CULL × CULLW × CULLP)︸ ︷︷ ︸
Revenue from culled animals
 (2)
FDRC︸ ︷︷ ︸
Cost to purchase cattle
= FRP︸︷︷︸
Feeder Price
× CPW︸ ︷︷ ︸
Placement weight of feeder
 (3)
YC︸︷︷︸
Yardage costs
= 0.30︸︷︷︸
Fixed Rate
× DOF︸︷︷︸
Days on feed
 (4)
FC︸︷︷︸
Feed costs
= FEED︸ ︷︷ ︸
Price of corn
×{ AFC︸︷︷︸
Feed conversion︸ ︷︷ ︸
× [CSW× (1−MORT− CULL)− CPW ] }︸ ︷︷ ︸
Total weight gain while at feedlot︸ ︷︷ ︸
Total amount of feed consumed while at feedlot
 (5)
IC︸︷︷︸
Interest costs
= {0.5 × [YC+ FC+ HC] +FDRC}︸ ︷︷ ︸
Entire feeder and half of all other costs
× (IR/365)︸ ︷︷ ︸
Interest rate
× DOF︸︷︷︸
Days on feed
 (6)
Table 1 describes each variable in detail.
Our objective was to determine how net return 
distributions change for high health-risk cattle as 
feedlots use different antimicrobial tiers across dif-
ferent placement weights and seasons. To do this, 
we calibrated the expected return in the simulation 
models by using breakeven (π  =  0) feeder cattle 
purchase prices for the “Upper Tier” antimicrobial 
used for each season and placement weight. This 
enabled us to compare net return distributions with 
and without metaphylaxis and across tiers of anti-
microbials used for metaphylaxis but only within its 
respective season and placement weight not across 
different seasons or placement weights.
Data
Ten large commercial feedlot operations lo-
cated in several Midwestern states provided two 
animal health and performance data sets used in 
this study. Cohorts are the common aggregate unit 
in commercial feedlot production systems. Cohort-
level animal health treatment information is the 
primary difference between the two data sets. We 
define cohorts (lots or pens) as animals purchased, 
assembled, and managed as an observable unit. 
When finished cattle are marketed, closeouts re-
cords record cohort-level animal performance and 
health information.
Observational data used in this study included 
a large panel data set comprising 48,341 cohorts of 
cattle (about 6 million head) placed on feed dur-
ing 1989–2008. This data set consisted of typical 
closeout information including HCs after feeding 
began excluding costs of metaphylaxis. These data 
were used to calibrate animal feeding performance 
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over time (i.e., ADG and AFC), which varied by 
season, location, and animal weight. The second 
observational data used comprised 1,357 cohorts 
of cattle (about 264,000 head) placed on feed dur-
ing 2014–2015. This more detailed, but smaller data 
set, documented both cohort and individual animal 
antimicrobial treatments associated with BRD ena-
bling us to estimate the cost of metaphylaxis and 
facilitated our stochastic simulation around cattle 
mortality. Table  2 displays summary statistics for 
the feedlot data.
Cattle Morbidity and Mortality
Metaphylaxis is expected to reduce morbidity 
and mortality in high health-risk feedlot cattle, but 
expected effectiveness varies by cattle placement 
weight, placement season, gender, and antimicro-
bial used (Nickell and White, 2010; DeDonder 
and Apley, 2015; Ives and Richeson, 2015). In our 
model, the impact of metaphylaxis on morbidity is 
reflected by its effects on three cattle performance 
parameters—average daily gain (ADG), average 
feed conversion (AFC), and HCs.
Multivariate Tobit, ordinary least squares, max-
imum likelihood, and linear mixed models (LMMs) 
have been used to model variation in ADG, 
veterinary/medication costs, and feed conversion in 
cattle across seasons, placement weights, etc. (Miller 
et al., 2005; Irsik et al., 2006; Belasco, 2008; Belasco 
et al., 2009; Dennis et al., 2018). In our study, cat-
tle performance parameters were quantified using 
an LMM with cohort size (i.e., the number of head 
per lot), year, and feedlot specific random effects to 
account for the hierarchical nature of cattle feed-
ing data where cohorts of cattle are nested within 
feedlots. Fixed effects for the estimation of ADG 
and AFC included the percentage of cohort level 
mortality (MORT × 100), the natural log of cat-
tle placement weight (lnCPW), whether the cohort 
were steers (STEER), and whether cattle were 
placed between October and March (WINTER). 
Cohort-level HCs are estimated in a similar for-
mat to ADG and AFC but WINTER is omitted 
because of the short time horizon of the data. In 
addition, binary variables indicating the antimi-
crobial tier given for metaphylaxis to a cohort are 
included (UPPER TIER or LOWER TIER). We 
estimated ADG and AFC equations using the large 
panel data set and associated HC using the more 
recent detailed data set.
We conditioned cattle mortality on cattle place-
ment weight, placement season, and antimicrobial 
used for metaphylaxis. Mortality distributions are 
Table 1. Feeding net return variables
Variables Description Value/Calculation
Simulated   
 ADG Average daily gain during feeding (lb/head/day) See Table 3
 AFC Average pounds of feed consumed per pound of weight gain (lb feed/lb gain) See Table 3
 DOF Number of days on feed (days)  
 FC Feed cost ($/head) See Eq. 5
 HC Animal health care cost including metaphylaxis, pull-and-treat, vaccinations, 
labor costs, etc. ($/head)
See Table 3
 IC Interest cost ($/head) See Eq. 6
 MORT Proportion of mortality in purchased group See Figure 1
 TR Total revenue from cattle sales ($/head) See Eq. 2
 YC Yardage cost of feeding cattle ($/head) See Eq. 4
 π Net feeding returns ($/head) See Eq. 1
Fixed   
 CPW Cattle purchase weight (lb/head) 600, 800
 CSW Finished animal weight (lb/head) if  animal reaches maturity 1,350
 CULL Proportion chronically ill animals culled from the remaining cohort 0.0140
 CULLP Price received for culled animals ($/lb) 0.75 × FP
 CULLW Average weight of culled animals (lb/head) 861
 FDRC Feeder cattle purchase cost ($/head) See Eq. 3
 FEED Corn price when cattle are placed on feed ($/lb) 0.0923
 FP Fed cattle sale price ($/lb) 1.48
 FRP Purchase price for CPW 600 (spring, winter) 800(spring, winter) lb ($/lb) 2.1461, 2.1379, 
1.7591, 1.7436
 IR Annualized interest rate 0.05
 SHRINK Proportion shrink in live weight when marketed 0.04
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known to be right-skewed with long tails, approx-
imated using a log-normal, (zero-inflated) negative 
binomial or a (zero-inflated) Poisson distribution 
(Babcock, 2010). We modeled all mortality distri-
butions as log-normal. Mortality distributions for 
the “Upper Tier” and “Lower Tier” antimicrobials 
were fit using the mean and standard deviation of 
mortality observed from proprietary production 
level data. However, the mortality of high health-
risk cattle not managed with metaphylaxis was not 
observed in feedlot data because feedlots give met-
aphylaxis to all cattle categorized as high health 
risk upon arrival. Thus, mortality distributions for 
high health-risk cattle not treated with metaphy-
laxis were approximated using ORs from a mixed 
treatment comparison (MTC) meta-analysis (Abell 
et  al., 2017). An MTC meta-analysis summarizes 
published randomized control antimicrobial tri-
als for BRD-related cattle morbidity and mortal-
ity and can be used to assess indirect comparisons 
across different antimicrobials used for metaphy-
laxis (O’Connor et al., 2013; Abell et al., 2017).
Differences Across Antimicrobials Used for 
Metaphylaxis
One important concern is the endogenous pro-
ducer choice to match the type of antimicrobial 
used for metaphylaxis to different cattle popula-
tions. The potential endogenous decision implies 
that simply comparing mortality outcomes in obser-
vational data between two different antimicrobial 
tiers is incorrect. Even after statistically matching 
cattle that received different tiers of antimicrobials 
based on observable feedlot and pen characteris-
tics, the antimicrobial choice is still nonrandom. 
Thus, in this context, traditional quasi-experimen-
tal methods to ascertain causality are insufficient. 
We solve this issue by developing a counterfactual 
mortality distribution that answers the following 
question: “Given we observe the mortality rate for 
a ‘Lower Tier’ antimicrobial, what would have been 
the observed mortality on that same cohort of cat-
tle had an ‘Upper Tier’ antimicrobial been used?”
To answer this proposed counterfactual ques-
tion, we first multiplied the estimated OR (0.62) for 
Tilmicosin (the “Lower Tier” antimicrobial) from the 
work of Abell et al. (2017) by a proposed hypothet-
ical “no metaphylaxis” mortality rate. This resulted 
in a hypothetical proposed “Lower Tier” antimicro-
bial mortality rate. We then iterated through different 
hypothetical proposed “no metaphylaxis” mortality 
values until the hypothetical proposed “Lower Tier” 
mortality rate matched the rate observed in the more 
recent intensive data. Then, the corresponding “Upper 
Tier” antimicrobial mortality was obtained by multi-
plying the resulting “no metaphylaxis” mortality rate 
by the estimated OR (0.16) for Tulathromycin (the 
“Upper Tier” antimicrobial) from the work of Abell 
et al. (2017). Our proposed method is loosely similar 
Table 2. Feedlot performance summary characteristics for two periods
Mean SD Min Max
January 1989–December 2008a
 Feed conversion (lb feed/lb gain) 6.07 0.59 3.01 9.91
 Average daily gain (lb gain/day) 2.96 0.56 1.51 5.98
 Mortality (%, MORT ×100) 1.24 1.76 0.00 25.64
 Placement weight (lb) 683.7 128.99 304.20 1,100.00
 Days on feed (days) 154.5 44.17 128.00 229.00
 Gender Steer 45.7% Heifer 54.3%
 Season Spring 25.1% Summer 27.4%
 Fall 24.3% Winter 23.2%
August 2014–December 2015b
 Feed conversion (lb feed/lb gain) 6.16 0.58 4.30 8.76
 Average daily gain (lb gain/day) 3.24 0.49 1.65 5.18
 Mortality (%) 2.52 3.19 0.00 26.78
 Placement weight (lb) 700.8 177.49 301.00 1096.00
 Days on feed (days) 192.8 67.20 87.00 443.30
 Gender Steer 55.0% Heifer 45.0%
 Season Spring 25.8% Summer 23.2%
 Fall 25.8% Winter 25.2%
aPeriod one has 48,341 cohorts/pen.
bPeriod two has 1,357 cohorts/pen.
Source: Proprietary feedlot data.
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to the Bayesian method used by Abell et al. (2017) to 
obtain differences in ORs for different types of anti-
microbials. Comparing the ORs obtained using our 
proposed method and those obtained by Abell et al. 
(2017) and find that they are not statistically different 
from each other. Thus, we applied our procedure for 
each of the four different placement weight by place-
ment season scenarios: 600 lb summer, 600 lb winter, 
800 lb summer, and 800 lb winter. Thus, by using this 
procedure resulting mortality rates, and subsequent 
net return distributions, could be compared within 
season and placement weights. The code for this opti-
mization method can be obtained by contacting the 
authors.
Simulation to Obtain Net Return Distributions
Our simulation method closely follows the 
method proposed by Dennis et al. (2018) to obtain 
net returns. We briefly describe those methods here 
and a more complete and detailed description can be 
found in the work of Dennis et al. (2018). The sim-
ulation method is as follows. First, we specified the 
high health-risk steer placement weight and place-
ment season. Second, we selected what antimicrobial 
tier was given, if any. Third, given these choices, we 
randomly selected a mortality rate from the corre-
sponding mortality distribution. Fourth, the steer 
placement, metaphylaxis decision, and random mor-
tality draw were multiplied by estimated beta coeffi-
cients from the LMM. Fifth, these stochastic ADG, 
AFC, and HC were used to calculate cattle feeding net 
return profit (π) from Eq. 1 for one cohort of cattle. 
Net return distributions for the 12 different scenarios 
(one gender, two placement weights, two placement 
seasons, three metaphylaxis options) were generated 
by repeating steps 1 to 5 using 5,000 Halton draws.
RESULTS
Descriptive Statistics
On average (min, max) cattle were placed at ap-
proximately 700 lb, gained 3 lb per day (1.5, 6.0), 
and had feed conversion of about 6 (3.0, 9.9) over 
155  days on feed (128, 229). Cattle were placed 
evenly across seasons. The average mortality for 
period one cattle was 1.24% (0.0, 25.6). A  large 
variation in mortality in both time periods was due 
to initial health status (high vs. low health risk), 
differing cattle populations (light vs. heavy weight), 
and placement season (winter vs. summer).
Estimated Morbidity
Table  3 displays parameter estimates for the 
estimated ADG, AFC, and HC models. Increased 
mortality was associated with lower daily gains 
(ADG  ↓), increased feed conversion (AFC ↑), and 
increased HCs (HC ↑). Higher placement weights 
were associated with higher feed conversions (AFC 
↑) and higher daily gains (ADG ↓). Placement weight 
was excluded from the HCs equation. Cattle placed 
during winter months had marginally higher daily 
gain and higher feed conversion. If an “Upper Tier” 
(“Lower Tier”) antimicrobial was used for metaphy-
laxis, feedlots incurred an estimated $28.61 ($23.97) 
per head cost for administration. Company random 
Table 3. LMM estimation for cattle performance that serves as a proxy for cattle morbidity
ADG AFC HC
Fixed effects    
 Constant –4.536 (0.10)a –1.129 (0.14) 5.936 (7.80)
 Mortality (MORT × 100) –0.059 (0.00) 0.050 (0.00) 1.541 (0.80)
 Log placement weight (lnCPW) 1.147 (0.01) 1.144 (0.02)  
 Steer (STEER) 0.238 (0.00) –0.272 (0.01) 1.782 (0.42)
 Oct–Mar (WINTER) 0.009 (0.00) 0.004 (0.01)  
 Antimicrobial (Upper Tier)   28.605 (0.85)
 Antimicrobial (Lower Tier)   23.969 (0.84)
Random effectsb    
 Company 0.016 0.016 14.417
 Cohort size 0.002 0.003 0.501
 Placement year 0.007 0.072  
Observations 48,341 48,341 1,357
REML convergence 41,678 75,791 9,334
aNumbers in parenthesis () are standard errors.
bVariances are reported for each random effect.
Source: Author’s calculations.
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effects suggested significant variation in company 
animal HCs.
Mortality Distributions
Figure  1 displays log-normal mortality distri-
butions for high health-risk steers conditional on 
placement weight, season, and antimicrobial used 
for metaphylaxis. Both tiers of antimicrobials used 
for metaphylaxis reduced expected mortality and 
the associated variance. Table 4 displays the param-
eters used to calculate the log-normal mortality dis-
tributions. Winter placements, across both weights, 
had larger mortality mean and variances. “Upper 
Tier” antimicrobials on average reduced mortal-
ity by more than “Lower Tier” antimicrobials and 
narrowed the associated variance. Not treating 
with metaphylaxis resulted in larger average mor-
tality and greater variation across all seasons and 
placement weights for high health-risk steers not 
managed with metaphylaxis. Thus, metaphylaxis 
reduced mortality in high health-risk steers but var-
ied by a class of antimicrobial used.
Net Return Distributions
Figure  2 displays net return distributions by 
cattle placement weight and season across three 
Figure 1. Mortality distributions for high health-risk steers by placement weight, placement season, and type of antimicrobial used for meta-
phylaxis. Antimicrobials used for metaphylaxis are categorized into “Upper” and “Lower” tiers based on Abell et al. (2017) who categorized them 
based on odds ratio (OR) confidence intervals.
Source: Abell et al. (2017) and author’s calculations.
Table 4. Mortality distributional assumptions for cattle type and antimicrobial treatment
Antimicrobial Placement weight (lb) Season Meana (%) SDa (%)
Upper Tier 600 Summer 1.07 0.91
Upper Tier 600 Winter 1.36 1.23
Upper Tier 800 Summer 0.94 0.55
Upper Tier 800 Winter 1.57 0.54
Lower Tier 600 Summer 4.14 3.77
Lower Tier 600 Winter 5.26 5.08
Lower Tier 800 Summer 3.66 2.30
Lower Tier 800 Winter 6.10 2.24
No Metaphylaxis 600 Summer 6.68 6.49
No Metaphylaxis 600 Winter 8.49 8.75
No Metaphylaxis 800 Summer 5.90 3.96
No Metaphylaxis 800 Winter 9.83 3.87
aTo account for endogenous producer decisions in using specific antimicrobials on specific cattle populations we use the odds ratios from Abell 
et al. (2017) for the lower tier antimicrobial and the mortality observed in lower tier antimicrobials to solve for the mortality of the control. We then 
use this control mortality and the odds ratios for the upper tier antimicrobial to obtain the mortality for the upper tier antimicrobial. This allows 
us to obtain the mortality of different antimicrobials on different cattle populations. A similar producer was used to find the standard deviations. 
In some cases, due to the absence of sufficient observations of steer pens (i.e., n ≥ 20), a pooled steer and heifer estimate was used.
Source: Proprietary feedlot data and Abell et al. (2017).
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animal health management decisions: “no met-
aphylaxis,” “Upper Tier” antimicrobial, and 
“Lower Tier” antimicrobial. “No metaphylaxis” 
net return distributions represent high health-
risk steer cohorts not managed with metaphy-
laxis upon arrival. The differences in expected 
net returns per head (averages) between admin-
istering an “Upper Tier” (“Lower Tier”) to “no 
metaphylaxis” were 1) $96.08 ($50.39) for 600 lb 
summer placements, 2)  $122.55 ($65.72) for 600 
lb winter placements, 3) $90.36 ($51.14) for 800 lb 
summer placements, and 4) $148.65 ($49.65) for 
800 lb winter placements. The difference between 
the Upper Tier and Lower Tier is the marginal 
net benefit of  using a certain antimicrobial tier for 
metaphylaxis. For example, the value of  admin-
istering an “Upper Tier” compared to a “Lower 
Tier” for 600 lb summer placements is $45.69 
(96.08−50.39 = 45.69). On average, “Upper Tier” 
antimicrobials were valued at $52.69 compared to 
“Lower Tier” antimicrobials across all placement 
weights and seasons.
Both antimicrobials used for metaphylaxis 
increased expected net returns and decreased net 
return variation. In other words, cattle feedlots 
were more certain that they will realize greater prof-
its on a cohort of high health-risk cattle when any 
tier of antimicrobial was used for metaphylaxis. 
Table 5 further summarizes the net return distribu-
tions displayed in Figure 2 reporting percentages of 
Table 5. Percentages of steer cohorts within net return ($/head) categoriesa
Net returns ($/head)
600 lb Placement weight 800 lb Placement weight
Summer (Apr–Sept) Winter (Oct–Mar) Spring (Apr–Sept) Winter (Oct–Mar)
Upper Lower Upper Lower Upper Lower Upper Lower
Metaphylaxis
 (-∞,-252) 0.00 1.64 0.00 4.40 0.00 0.04 0.00 0.04
 (-251, -51) 1.64 37.56 3.64 40.32 0.08 41.72 0.00 76.64
 (-50, 0) 34.12 40.56 34.44 33.12 41.68 51.68 47.80 23.00
 (0, 50) 64.24 20.24 61.92 22.16 58.24 6.56 52.20 0.32
 (>51) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No metaphylaxis
 (-∞,-252) 7.08 7.08 12.56 12.56 2.16 2.16 4.68 4.68
 (-251, -51) 35.64 35.64 34.56 34.56 44.04 44.04 79.68 79.68
 (-50, 0) 24.24 24.24 21.00 21.00 34.12 34.12 14.56 14.56
 (0, 50) 33.04 33.04 28.16 28.16 19.68 19.68 1.08 1.08
 (51, +∞) 0.00 0.00 3.72 3.72 0.00 0.00 0.00 0.00
aAntimicrobials used for metaphylaxis are categorized into “upper” and “lower” tiers based on Abell et al. (2017) who categorized them based 
on odds ratio (OR) confidence intervals.
Source: Author’s calculations.
Figure 2. Net return distributions for high health-risk steers by placement weight, placement season, and type of antimicrobial used for meta-
phylaxis. Data used to generate the distributions are obtained from the simulation described in the main body of the text.
Source: Author’s calculations.
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the 5,000 simulated cohorts falling within expected 
net return ranges conditional on cattle placement 
weight, placement season, and antimicrobial used.
Metaphylaxis administered to high health-
risk cattle substantially reduced the probability 
of  large losses. For example, for a cohort of  600 
lb summer placed high health-risk steers treated 
with an “Upper Tier” antimicrobial, there was 
a 1.64% (0.00% + 1.64%) chance of  realizing a 
loss of  more than $50 per head; 0.00% probability 
of  losses less than −$251 per head; 1.64% prob-
ability of  losses between −$51 and −$251. If  high 
health-risk steers were not treated, they faced a 
42.72% (7.08% + 35.64%) probability of  losing 
more than $50 per head. For a cohort of  600 
lb high health-risk winter placed steers treated 
with a “Lower Tier” they faced a 44.72% (4.40% 
+ 40.32%) chance of  realizing at least a $50 per 
head loss. Not treating this same cohort resulted 
in a 47.12% (12.56% + 34.56%) probability of 
realizing at least a $50 per head loss. Taking this 
result further, large losses in excess of  $250 per 
head had a 7% to 12% probability of  being real-
ized for high health-risk 600 lb placed steers not 
treated with any antimicrobial compared to gen-
erally less than 0% to 4% probability of  such large 
losses regardless of  season or antimicrobial tier 
used for metaphylaxis.
Heavier weight placements were less likely to 
have large negative returns since the proportion of 
cattle that died was relatively small compared to 
lighter placements. For example, a cohort of 600 
lb summer placed high health-risk steers adminis-
tered an “Upper Tier” antimicrobial faced a 1.64% 
(0.00% + 1.64%) chance of realizing a loss greater 
than $50 per head compared to 0.08% (0.00% + 
0.08%) for a cohort of 800 lb steers placed at the 
same time and administered the same tier of anti-
microbial. Summer placed high health-risk steers 
were expected to have a lower risk of large losses 
compared to winter placements. For example, a 
cohort of 800 lb summer placed high health-risk 
steers treated with a “Lower Tier” antimicrobial 
had a 41.76% (0.04% + 41.72%) probability of real-
izing a loss of more than $50 per head compared 
to 76.68% (0.04% + 76.64%) for the same cohort 
placed in winter.
DISCUSSION
The objective of this study was to estimate net 
return and return risk between “Upper Tier” and 
“Lower Tier” antimicrobials used for metaphylaxis 
to manage BRD and a “no metaphylaxis” option in 
high health-risk feedlot cattle. We used a stochastic 
net return simulation model to determine how net 
return and return risk varied across cattle popula-
tions placed in different seasons and given different 
tiers of antimicrobials. As such, the outcomes are 
broad enough to encompass a variety of situations 
relevant to the feedlot industry.
The decision of whether to manage high health-
risk cattle with metaphylaxis, and if  so, which tier 
of antimicrobial to use, is a difficult question to an-
swer in part because the decisions are made with 
incomplete information. Realized health outcomes 
are only known after cattle have finished feeding 
whereas metaphylaxis decisions are generally made 
at the time of cattle placement. Thus, we must rely 
on expected return distributions with and without 
the use of metaphylaxis to assess their expected 
economic value.
Metaphylaxis modifies cattle morbidity and 
mortality (Nickell and White, 2010; Tennant 
et  al., 2014). In our model morbidity impacts 
were reflected through the decrease in cattle per-
formance parameters (ADG, AFC, and HCs). 
Higher placement weights were associated with 
higher ADG and higher AFC consistent with ran-
domized control trials that as placement weight 
increases so does AFC (Nickell and White, 2010). 
Positive correlations between HC and mortality 
are consistent with both trial and production-level 
data as both are associated with the rate at which 
feedlots are pulling and treating cattle. Estimated 
lower cattle performance in winter months is 
consistent with literature demonstrating cattle 
devote more energy to body temperature mainte-
nance during colder months (Mader et al., 2010). 
“Upper Tier” antimicrobials are more expensive 
consistent with price premiums for a perceived 
higher quality product. Both antimicrobial tier 
cost estimates are generally consistent with results 
from the National Animal Health Monitoring 
Survey that reported average antimicrobial costs 
of  $23.50 per head to administer metaphylaxis 
to feeder cattle (United States Department of 
Agriculture, 2013).
Mortality distributions were estimated as 
log-normal and fit using the mean and standard 
deviation of mortality for the different tiers of anti-
microbials used for metaphylaxis and a “no meta-
phylaxis” option. Metaphylaxis modifies both the 
mean and standard deviation of mortality distri-
butions consistent with previous literature (Dennis 
et al., 2018). Results also align with the knowledge 
that heavier cattle and summer placed cattle have 
lower mean mortality with less variation (Babcock 
1100 Dennis et al.
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et al., 2009). “Upper Tier” antimicrobials reduced 
both the variation and mean mortality values across 
all placement weights and placement seasons (Abell 
et al., 2017). Likewise, feedlots opting to use a “no 
metaphylaxis” option on high health-risk cattle sig-
nificantly increases variation and mean mortality 
consistent with the idea that using any antimicro-
bial on high health-risk cattle is beneficial (Nickell 
and White, 2010).
An interesting result relative to the decision to 
manage high health-risk steer cohorts with meta-
phylaxis is that high net returns (low mortality) can 
still, by chance, be realized whether or not cattle are 
managed with metaphylaxis. For example, for 600 
lb high risk steers placed, regardless of season or 
antimicrobial administered for metaphylaxis would 
expect more than 35% of the time to realize posi-
tive net returns. However, there is still at least a 
20% chance that a high-risk cohort would realize 
positive net returns if  not administered metaphy-
laxis. This is because there is a chance that high 
health-risk cattle, even if  not given metaphylaxis, 
will remain sufficiently healthy and not have high 
mortality.
Expected return alone is insufficient to assess 
the viability of  metaphylaxis if  return risk also 
matters. Treating all high health-risk cattle with 
metaphylaxis broadly increases expected net re-
turn and reduces return variability. This makes 
the use of  metaphylaxis as a health management 
practice appears obvious. However, the change 
in expected return, as well as the risk mitigated 
through metaphylaxis of  all high-risk cattle, varies 
by placement season, tier of  antimicrobial used, 
and cattle placement weight. Lighter weight high 
health-risk cattle are expected to realize greater 
returns and more return risk mitigation through 
metaphylaxis regardless of  the season and anti-
microbial tier (of  those investigated here), than 
heavier weight placements.
The value of meeting production or market-
ing contract agreements is a value of metaphylaxis 
not currently captured in the simulation. Feedlots 
can use metaphylaxis as a preventative measure to 
help enable them to have enough cattle reach har-
vest weight to comply with agreements/contracts 
with meat packers. Thus, the value of metaphylaxis 
represents more than just the loss in input costs as 
currently calculated. Thus, estimated values likely 
serve as a lower bound to the value of metaphylaxis 
for feedlots.
Our simulation had feedlots sell cattle on a live 
weight basis and did not allow for any discounts or 
premiums for carcass yield and quality grade. Thus, 
if  carcass quality is affected by the use of meta-
phylaxis then the net value of metaphylaxis would 
change based on premiums and/or discounts for 
yield and quality grade.
An important issue, not addressed in this study 
but deserves more consideration given our findings, 
is how to identify and categorize high health-risk 
cattle. The occurrence of respiratory disease in 
some cattle in a cohort, BRD problems in cattle pre-
viously received from the same source, and known 
lack of preconditioning are all important in deter-
mining whether a group of cattle should be man-
aged with metaphylaxis (United States Department 
of Agriculture, 2019). Feedlots can discount high 
health-risk cattle at purchase to offset perceived 
production and HCs. High-risk cattle are worthless 
to the feedlot than otherwise similar low-risk cattle, 
since they can require higher HCs and have greater 
morbidity and mortality risk with more variable 
net returns. Feedlots that are able to correctly cat-
egorize cattle health risk could capitalize on these 
discounts.
In practice high health-risk cattle are managed 
with metaphylaxis and feedlots do not observe net 
return outcomes from high health-risk cattle not 
managed with metaphylaxis. While positive profits 
can be obtained, feedlots may perceive the reali-
zation of  major net return losses to be worse than 
the potential positive profits from not managing 
with metaphylaxis. Likewise, the error associated 
with mis-categorization of  cattle into health-risk 
bins further complicates this decision process. We 
expect with the more accurate categorization of 
cattle into health-risk status upon feedlot arrival, 
health management strategies could be refined. 
Of  course, the cost of  acquiring additional infor-
mation for more accurate animal health status 
classification may exceed the value. For example, 
chute-side diagnostics aimed at identifying sick 
cattle on arrival may be too costly or time and 
labor prohibitive.
The estimates from our study should be held in 
the context of the fed and feeder cattle price levels 
used. Previous work indicates that changing input 
and output price levels can impact the value of met-
aphylaxis (Dennis et al., 2018) and in our case the 
value for each antimicrobial tier. The average fed 
cattle price used in this simulation was $148/cwt 
(see Table 1). Higher fed cattle prices create greater 
value associated with metaphylaxis, all else held 
equal. As fed cattle prices increase, the cost of mor-
tality increases. As such, fed cattle price has impor-
tant impacts on the value of metaphylaxis because 
higher fed cattle prices are associated with higher 
1101Net return distributions for metaphylaxis
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feeder cattle prices and any mortality has a greater 
economic cost to the feedlot.
CONCLUSIONS
Results identified the net return and return 
risk of using two different antimicrobial tiers for 
metaphylaxis compared to no metaphylaxis, in dif-
ferent high-risk cattle populations. Likewise, we 
quantified the relative benefit of using an “Upper 
Tier” antimicrobial compared to a “Lower Tier” 
antimicrobial for metaphylaxis. “Upper Tier” anti-
microbial produced higher net returns and lower re-
turn risk compared to “Lower Tier” antimicrobials. 
Both antimicrobial tiers were valued more than not 
administering metaphylaxis, but this expected value 
varies by cattle placement season and placement 
weight. Further research is needed to determine 
how feedlots substitute between these tiers of anti-
microbials in an attempt to match animal health 
risk with antimicrobial tier effectiveness and cost in 
an effort to maximize profit.
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